Related Experiment Video
Updated: Apr 25, 2026
07:11
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
7.7K
Association Between Zolpidem Use and Glaucoma Risk: A Taiwanese Population-Based Case-Control Study
Yi-Hao Ho1, Yue-Cune Chang, Wei-Cheng Huang
1Department of Ophthalmology, China Medical University Hospital.
Journal of Epidemiology
|August 26, 2014
Summary
This study suggests that zolpidem use may increase glaucoma risk. Zolpidem users, especially those with higher dosages, showed a significantly increased risk of developing glaucoma.
Area of Science:
- Ophthalmology
- Pharmacology
- Epidemiology
Background:
- The association between zolpidem (a sedative-hypnotic) and glaucoma risk is not well-established.
- Previous research has not specifically investigated this relationship within the Taiwanese population.
Purpose of the Study:
- To investigate the potential link between zolpidem use and the subsequent development of glaucoma.
- To assess if zolpidem exposure increases glaucoma risk in a Taiwanese cohort.
Main Methods:
- A 1:4 matched case-control study utilizing Taiwanese National Health Insurance data (2001-2010).
- Cases were newly diagnosed glaucoma patients; controls were matched non-glaucoma subjects.
- Logistic regression models analyzed zolpidem exposure, dosage, and medical comorbidities as risk factors.
Main Results:
- Zolpidem use was significantly more prevalent in glaucoma patients (2.8%) compared to controls (2.0%).
- Zolpidem use was associated with a 1.19-fold increased risk of glaucoma (adjusted OR: 1.19, 95% CI: 1.02-1.38).
- High-dose zolpidem users (average >200 mg/year) exhibited a 1.31-fold increased risk (adjusted OR: 1.31, 95% CI: 1.03-1.68).
Conclusions:
- The findings suggest a potential association between zolpidem use and an elevated risk of subsequent glaucoma.
- Further research is warranted to confirm these findings and elucidate the underlying mechanisms.
